US Tobacco Giant Backs Dutch Cannabis Grower Acquisition Amid Legalization Trial
US tobacco giant Altria is backing the €57.5 million acquisition of Dutch cannabis grower CanAdelaar by Cronos, raising concerns among experts about industry influence on the Netherlands’ legalization experiment
Key Points
- 1CanAdelaar, the Netherlands’ largest licensed cannabis grower, is being acquired by Cronos for €57.5 million
- 2Cronos is 41% owned by US tobacco giant Altria, maker of Marlboro cigarettes
- 3Addiction experts warn that tobacco industry tactics could influence the Dutch cannabis legalization trial
- 4At least four pro-cannabis scientific papers were authored by researchers funded by a Philip Morris International subsidiary
- 5The Dutch government’s cannabis supply chain experiment is set to run through 2029
A major shift in the Dutch cannabis landscape is underway as CanAdelaar, the Netherlands’ largest licensed cannabis grower, is set to be acquired by Canadian firm Cronos, which is 41% owned by US tobacco giant Altria—maker of Marlboro cigarettes. The acquisition, valued at €57.5 million, is expected to conclude later this year, pending regulatory approval and a mandatory background check known as Bibob. This move comes as the Netherlands conducts a pioneering government trial to create a fully legal cannabis supply chain, licensing 10 growers to serve coffeeshops across 10 municipalities
The involvement of Altria in the Dutch cannabis market has sparked significant concern among addiction experts, who fear that Big Tobacco's marketing and lobbying tactics could infiltrate the country's carefully regulated legalization experiment. "The industry has no interest in curbing long-term use," said Marc Willemsen of the Trimbos Institute, a Dutch public health body. Tom Bart from the Jellinek addiction service highlighted the risk of aggressive marketing, citing the tobacco industry's history of leveraging influencers and social media to promote vaping products
Further scrutiny arose after an investigation revealed that Aspeya, a Philip Morris International subsidiary, funded nine out of eleven authors of at least four scientific papers supporting cannabis compounds' benefits. Kevin Jenniskens of Cochrane Netherlands noted, "Such industry-funded reviews are red flags and that results tend to present findings in favour of those that commissioned them." These revelations have intensified debate over the potential influence of major multinational corporations on public health policy and scientific research
In response to these concerns, Cronos has emphasized its independence from tobacco interests, stating that Altria does not control its daily operations, commercial strategies, or branding. CanAdelaar also stressed it operates independently of Altria. Meanwhile, Philip Morris International reiterated its focus on transitioning to smoke-free alternatives, and Aspeya clarified that all funding and potential conflicts were transparently disclosed in the relevant scientific publications
As the Dutch experiment continues through 2029, with CanAdelaar producing an estimated 20,000 kilos of cannabis annually—enough for approximately 60 million joints—OG Lab notes that this acquisition marks a pivotal moment for Europe's cannabis industry. The outcome will serve as a key indicator of how global corporate interests may shape the future of cannabis regulation, marketing, and research across the continent
